flecainide has been researched along with Ventricular Fibrillation in 78 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of quinidine bisulfate (mean dose, 1483+/-240 mg) on the prevention of inducible and spontaneous ventricular fibrillation (VF) were prospectively evaluated in 25 patients (24 men, 1 woman; age, 19 to 80 years) with Brugada syndrome." | 8.82 | Efficacy of quinidine in high-risk patients with Brugada syndrome. ( Belhassen, B; Glick, A; Viskin, S, 2004) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 8.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "To study refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation (VF) by flecainide." | 7.72 | Refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation by flecainide. ( Amitzur, G; Eldar, M; Kraft, P; Leor, J; Mueller, M; Novikov, I; Raichlin, E; Schoels, W; Shenkar, N, 2003) |
| "The flecainide test is widely used in Brugada syndrome." | 7.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " Under control conditions and after flecainide, verapamil, or d,l-sotalol, the dominant frequency (FrD), type of activation maps, conduction velocity, functional refractory period, and wavelength (WL) of excitation were determined during ventricular fibrillation (VF)." | 7.70 | Alteration of ventricular fibrillation by flecainide, verapamil, and sotalol: an experimental study. ( Cánoves, J; Chorro, FJ; Guerrero, J; López-Merino, V; Mainar, L; Sanchis, J; Such, L, 2000) |
| "In 22 anesthetized mongrel dogs, spectral methods were used to analyze the surface electrocardiogram (ECG) for the time course of the dominant frequency in ventricular fibrillation and its modifications under the influence of amiodarone, diltiazem, and flecainide." | 7.69 | Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study. ( Bataller, M; Chorro, FJ; Cortina, J; Espí, J; Guerrero, J; López-Merino, V; Ruipérez, JA; Sánchez-Muñoz, JJ; Sanchis, J, 1996) |
| "Encainide and flecainide have a low efficacy rate and a high incidence of worsening of arrhythmia in patients with sustained ventricular arrhythmias, particularly when this condition is associated with poor left ventricular function." | 7.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 7.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 7.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "A combination of oral flecainide and mexiletine was given to 11 patients in whom monotherapy with one of these drugs was ineffective for the suppression of inducible ventricular tachycardia or fibrillation." | 7.68 | Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias. ( Clement, DL; Jordaens, LJ; Robbens, E; Tavernier, R; Vanmeerhaeghe, X, 1990) |
| "The changes produced by verapamil, bretylium and flecainide in both ventricular fibrillation threshold (VFT) and ventricular repetitive response threshold (VRRT) were studied in 20 closed-chest dogs anaesthetized with pentobarbital." | 7.68 | Changes in canine ventricular fibrillation threshold induced by verapamil, flecainide and bretylium. ( Alberola, A; Burguera, MA; Chorro, FJ; Lopez-Merino, V; Quesada, A; Sanchis, J; Such, L, 1993) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 7.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "A 32-year-old woman with prolapsed mitral valve was treated with flecainide because of an episode of primary ventricular fibrillation." | 7.67 | Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity. ( Follath, F; Hoffmann, A; Wenk, M, 1986) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 7.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 7.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 5.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 5.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "The effects of quinidine bisulfate (mean dose, 1483+/-240 mg) on the prevention of inducible and spontaneous ventricular fibrillation (VF) were prospectively evaluated in 25 patients (24 men, 1 woman; age, 19 to 80 years) with Brugada syndrome." | 4.82 | Efficacy of quinidine in high-risk patients with Brugada syndrome. ( Belhassen, B; Glick, A; Viskin, S, 2004) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 4.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "The flecainide test is widely used in Brugada syndrome." | 3.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| "These findings demonstrate that, in Brugada syndrome, spontaneous or ajmaline-induced changes in the surface ECG may be paralleled by significant variations in the right ventricular endocardial electrogram that may result in ICD malfunction." | 3.70 | Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome. ( Bella, PD; Carbucicchio, C; Schmidinger, H; Stix, G, 2000) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 3.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| "A combination of oral flecainide and mexiletine was given to 11 patients in whom monotherapy with one of these drugs was ineffective for the suppression of inducible ventricular tachycardia or fibrillation." | 3.68 | Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias. ( Clement, DL; Jordaens, LJ; Robbens, E; Tavernier, R; Vanmeerhaeghe, X, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 3.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "Encainide and flecainide have a low efficacy rate and a high incidence of worsening of arrhythmia in patients with sustained ventricular arrhythmias, particularly when this condition is associated with poor left ventricular function." | 3.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 3.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "We report on a 46-year-old woman with ventricular tachycardia and ventricular fibrillation after starting antiarrhythmic drug therapy with flecainide." | 3.67 | [Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. ( Jung, W; Kamradt, T; Lüderitz, B; Manz, M; Mletzko, R; Vogel, F, 1989) |
| "To assess flecainide's ability to suppress ventricular fibrillation during reperfusion, we compared flecainide acetate (2 mg/kg i." | 3.67 | Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. ( Bolster, DE; Lederman, SN; Strauss, HC; Wenger, TL, 1989) |
| "A 32-year-old woman with prolapsed mitral valve was treated with flecainide because of an episode of primary ventricular fibrillation." | 3.67 | Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity. ( Follath, F; Hoffmann, A; Wenk, M, 1986) |
| " Antiarrhythmic effects of flecainide and its enantiomers were assessed in two different animal models, chloroform-induced ventricular fibrillation in mice and ouabain-induced ventricular tachycardia in dogs." | 3.67 | Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers. ( Banitt, EH; Newmark, RA; Schmid, JR, 1986) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 3.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 3.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| " 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide acetate (flecainide, R 818, Tambocor) caused a significant increase of the atrial and ventricular fibrillation thresholds." | 3.66 | Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs. ( Bender, F; Gülker, H; Heuer, H; Thale, J, 1983) |
| "Brugada syndrome is characterized by an ST segment elevation in leads V1-V3 and a high incidence of ventricular fibrillation (VF)." | 2.69 | Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. ( Aihara, N; Antzelevitch, C; Kamakura, S; Kurita, T; Shimizu, W; Sunagawa, K; Suyama, K; Taguchi, A; Takaki, H, 2000) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | 2.38 | Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. ( Anderson, JL, 1990) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) has led to serious reconsideration of both the benefit-risk ratio of antiarrhythmic drug therapy and the appropriate therapeutic approach to various cardiac arrhythmias." | 2.38 | Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. ( Anderson, JL, 1990) |
| "Flecainide testing was performed at each follow-up visits ≤6 months." | 1.42 | Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. ( Berruezo, A; Brugada, J; Ciconte, G; Giannelli, L; Manguso, F; Pappone, C; Santinelli, V; Vicedomini, G, 2015) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "An amiodarone infusion was started and continued over a period of 72 h." | 1.31 | Amiodarone used in successful resuscitation after near-fatal flecainide overdose. ( Board, PN; Siegers, A, 2002) |
| "None of the three drugs increased arrhythmia incidence." | 1.31 | Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts. ( Curtis, MJ; Farkas, A, 2002) |
| "Flecainide 2 mg kg(-1) was administered i." | 1.30 | Effects of lidocaine and mexiletine on defibrillation energy requirements in animals treated with flecainide. ( Imagawa, N; Sato, S, 1998) |
| "When examined on premature beats, AT was delayed, depending on the coupling interval and the fiber direction when saline, flecainide or lidocaine was infused." | 1.30 | Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine. ( Kondo, T; Kubota, I; Tachibana, H; Tomoike, H; Yamaki, M, 1997) |
| "Ventricular fibrillation was induced by endocardial electrical stimulation in pigs anaesthetised with pentobarbitone sodium (30 mg/kg intravenously)." | 1.29 | Effects of blockade of fast and slow inward current channels on ventricular fibrillation in the pig heart. ( Adgey, AA; Allen, JD; Devine, AB; Stewart, AJ, 1996) |
| "Mexiletine tended to increase DFT [from 4." | 1.29 | Prolongation of intraventricular conduction time associated with fatal [correction of fetal] impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents. ( Ajiki, K; Inoue, H; Kuo, TT; Murakawa, Y; Nakajima, T; Oikawa, N; Sezaki, K; Sugimoto, T; Usui, M; Yamashita, T, 1995) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 1.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Flecainide acetate is a recently approved class 1c antiarrhythmic agent indicated for patients with serious ventricular arrhythmias." | 1.27 | Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. ( Jones, DL; Klein, GJ; McQuinn, RL; Szabo, TS, 1988) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 1.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (23.08) | 18.7374 |
| 1990's | 30 (38.46) | 18.2507 |
| 2000's | 15 (19.23) | 29.6817 |
| 2010's | 13 (16.67) | 24.3611 |
| 2020's | 2 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ryan, K | 1 |
| Benz, P | 1 |
| Zosel, A | 1 |
| Farkas, A | 2 |
| Theobald, J | 1 |
| Colangelo, T | 1 |
| Johnson, D | 1 |
| Ho, R | 1 |
| Poli, S | 1 |
| Toniolo, M | 1 |
| Maiani, M | 1 |
| Zanuttini, D | 1 |
| Rebellato, L | 1 |
| Vendramin, I | 1 |
| Dametto, E | 1 |
| Bernardi, G | 1 |
| Bassi, F | 1 |
| Napolitano, C | 2 |
| Livi, U | 1 |
| Proclemer, A | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 3 |
| Ghosh, J | 1 |
| McGuire, MA | 1 |
| Kilborn, MJ | 1 |
| Singarayar, S | 1 |
| Medi, C | 1 |
| Sy, RW | 1 |
| Kamakura, T | 1 |
| Wada, M | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Miyamoto, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Aiba, T | 1 |
| Takaki, H | 2 |
| Yasuda, S | 1 |
| Ogawa, H | 1 |
| Shimizu, W | 2 |
| Makiyama, T | 1 |
| Kimura, T | 1 |
| Kamakura, S | 2 |
| Kusano, K | 1 |
| Brugada, J | 2 |
| Pappone, C | 1 |
| Berruezo, A | 1 |
| Vicedomini, G | 1 |
| Manguso, F | 1 |
| Ciconte, G | 1 |
| Giannelli, L | 1 |
| Santinelli, V | 1 |
| Ahn, J | 2 |
| Roh, SY | 1 |
| Lee, DI | 1 |
| Shim, J | 1 |
| Choi, JI | 1 |
| Kim, YH | 2 |
| Mahida, S | 1 |
| Derval, N | 1 |
| Letsas, KP | 1 |
| Weber, R | 1 |
| Astheimer, K | 1 |
| Kalusche, D | 1 |
| Arentz, T | 1 |
| Lebreiro, A | 1 |
| Sousa, A | 1 |
| Silva, A | 1 |
| Campos, J | 1 |
| Maciel, MJ | 1 |
| Lu, HR | 1 |
| Rohrbacher, J | 1 |
| Vlaminckx, E | 1 |
| Van Ammel, K | 1 |
| Yan, GX | 1 |
| Gallacher, DJ | 1 |
| Osadchii, OE | 2 |
| Soltysinska, E | 1 |
| Olesen, SP | 1 |
| Cabezón Ruiz, S | 1 |
| Errazquin Sáenz de Tejada, F | 1 |
| Pedrote Martínez, A | 1 |
| Morán Risco, JE | 1 |
| Marín Morgado, J | 1 |
| Fernández Pérez, JM | 1 |
| Gasparini, M | 1 |
| Priori, SG | 1 |
| Mantica, M | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Simonini, S | 1 |
| Ackland, F | 1 |
| Singh, R | 1 |
| Thayyil, S | 1 |
| Amitzur, G | 1 |
| Shenkar, N | 1 |
| Mueller, M | 1 |
| Kraft, P | 1 |
| Novikov, I | 1 |
| Eldar, M | 2 |
| Leor, J | 1 |
| Raichlin, E | 1 |
| Schoels, W | 1 |
| Belhassen, B | 1 |
| Glick, A | 1 |
| Viskin, S | 1 |
| Yokoi, H | 1 |
| Haghjoo, M | 1 |
| Arya, A | 1 |
| Emkanjoo, Z | 1 |
| Sadr-Ameli, MA | 1 |
| Hug, C | 1 |
| Koliopoulos, N | 1 |
| Tardy, C | 1 |
| Errera, J | 1 |
| Puech, P | 1 |
| Heuer, H | 1 |
| Gülker, H | 1 |
| Thale, J | 1 |
| Bender, F | 1 |
| Hellestrand, KJ | 1 |
| Crijns, HJ | 2 |
| Wiesfeld, AC | 1 |
| Posma, JL | 1 |
| Lie, KI | 2 |
| Stramba-Badiale, M | 1 |
| Lazzarotti, M | 1 |
| Facchini, M | 1 |
| Schwartz, PJ | 1 |
| Usui, M | 2 |
| Inoue, H | 2 |
| Saihara, S | 1 |
| Sugimoto, T | 2 |
| Murakawa, Y | 1 |
| Kuo, TT | 1 |
| Sezaki, K | 1 |
| Nakajima, T | 1 |
| Yamashita, T | 1 |
| Ajiki, K | 1 |
| Oikawa, N | 1 |
| Goldstein, S | 1 |
| Brooks, MM | 1 |
| Ledingham, R | 1 |
| Kennedy, HL | 1 |
| Epstein, AE | 1 |
| Pawitan, Y | 1 |
| Bigger, JT | 1 |
| Quesada, A | 1 |
| Sanchis, J | 3 |
| Chorro, FJ | 3 |
| Burguera, MA | 1 |
| Alberola, A | 1 |
| Such, L | 2 |
| Lopez-Merino, V | 3 |
| Gout, B | 1 |
| Nichols, AJ | 1 |
| Feuerstein, GZ | 1 |
| Bril, A | 1 |
| Sweeney, RJ | 1 |
| Gill, RM | 1 |
| Steinberg, MI | 1 |
| Reid, PR | 2 |
| Sánchez-Muñoz, JJ | 1 |
| Cortina, J | 1 |
| Bataller, M | 1 |
| Guerrero, J | 2 |
| Espí, J | 1 |
| Ruipérez, JA | 1 |
| Stewart, AJ | 1 |
| Allen, JD | 1 |
| Devine, AB | 1 |
| Adgey, AA | 1 |
| Aupetit, JF | 4 |
| Loufoua-Moundanga, J | 3 |
| Faucon, G | 3 |
| Timour, Q | 4 |
| Kondo, T | 1 |
| Yamaki, M | 4 |
| Kubota, I | 4 |
| Tachibana, H | 4 |
| Tomoike, H | 4 |
| Eckardt, L | 1 |
| Haverkamp, W | 1 |
| Göttker, U | 1 |
| Madeja, M | 1 |
| Johna, R | 1 |
| Borggrefe, M | 1 |
| Breithardt, G | 1 |
| Sato, S | 1 |
| Imagawa, N | 1 |
| Krishnan, SC | 1 |
| Josephson, ME | 1 |
| Watanabe, T | 3 |
| Yamauchi, S | 2 |
| Itoh, E | 1 |
| Suzuki, K | 1 |
| Tanabe, Y | 1 |
| Bui-Xuan, B | 1 |
| Kioueh, I | 3 |
| Loufoua, J | 1 |
| Frassati, D | 1 |
| Cánoves, J | 1 |
| Mainar, L | 1 |
| Stix, G | 1 |
| Bella, PD | 1 |
| Carbucicchio, C | 1 |
| Schmidinger, H | 1 |
| Antzelevitch, C | 1 |
| Suyama, K | 1 |
| Kurita, T | 1 |
| Taguchi, A | 1 |
| Aihara, N | 1 |
| Sunagawa, K | 1 |
| Alings, M | 1 |
| Dekker, L | 1 |
| Sadée, A | 1 |
| Wilde, A | 1 |
| Curtis, MJ | 1 |
| Siegers, A | 1 |
| Board, PN | 1 |
| Lombardi, F | 1 |
| Torzillo, D | 1 |
| Sandrone, G | 1 |
| Dalla Vecchia, L | 1 |
| Cappiello, E | 1 |
| Omar, S | 1 |
| Chevrel, G | 1 |
| van Wijk, LM | 1 |
| Kingma, HJ | 1 |
| van Gilst, WH | 1 |
| van Gelder, IC | 1 |
| Wesseling, H | 1 |
| Jordaens, LJ | 1 |
| Tavernier, R | 1 |
| Vanmeerhaeghe, X | 1 |
| Robbens, E | 1 |
| Clement, DL | 1 |
| Palitzsch, KD | 1 |
| Bode, H | 1 |
| Huck, K | 1 |
| Usadel, KH | 1 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Muir, AW | 1 |
| Boersma, L | 1 |
| Kirchhof, C | 1 |
| Allessie, M | 1 |
| Gerentes-Chassagne, I | 1 |
| Anderson, JL | 3 |
| Herre, JM | 1 |
| Titus, C | 1 |
| Oeff, M | 1 |
| Franz, MR | 1 |
| Griffin, JC | 1 |
| Scheinman, MM | 1 |
| Sternick, EB | 1 |
| Azevedo Sobrinho, AL | 1 |
| Barbosa, MR | 1 |
| Fantini, F | 1 |
| Gontijo, B | 1 |
| Vrandecic, MO | 1 |
| Somberg, JC | 1 |
| Miura, D | 1 |
| Keefe, DL | 1 |
| Szabo, TS | 1 |
| Jones, DL | 1 |
| McQuinn, RL | 1 |
| Klein, GJ | 1 |
| Lederman, SN | 1 |
| Wenger, TL | 1 |
| Bolster, DE | 1 |
| Strauss, HC | 1 |
| Falk, RH | 1 |
| Hernandez, R | 1 |
| Mann, DE | 1 |
| Breckinridge, S | 1 |
| Williams, GR | 1 |
| Reiter, MJ | 1 |
| Mletzko, R | 1 |
| Jung, W | 1 |
| Manz, M | 1 |
| Kamradt, T | 1 |
| Vogel, F | 1 |
| Lüderitz, B | 1 |
| Kou, WH | 1 |
| Nelson, SD | 1 |
| Lynch, JJ | 2 |
| Montgomery, DG | 2 |
| DiCarlo, L | 1 |
| Anastasiou-Nana, MI | 1 |
| Stewart, JR | 1 |
| Crevey, BJ | 1 |
| Yanowitz, FG | 1 |
| Lutz, JR | 1 |
| Johnson, TA | 1 |
| Cowan, JC | 1 |
| Holt, DW | 1 |
| Bexton, RS | 1 |
| Reid, DS | 1 |
| Klein, KL | 1 |
| Holloway, JD | 1 |
| Glasser, SP | 1 |
| DiCarlo, LA | 1 |
| Cha, YM | 1 |
| Zhang, AP | 1 |
| Liu, L | 1 |
| Sun, JP | 1 |
| Huang, W | 1 |
| Hoffmann, A | 1 |
| Wenk, M | 1 |
| Follath, F | 1 |
| Banitt, EH | 1 |
| Schmid, JR | 1 |
| Newmark, RA | 1 |
| Platia, EV | 1 |
| Estes, M | 1 |
| Heine, DL | 1 |
| Griffith, LS | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients[NCT02641431] | 135 participants (Actual) | Interventional | 2015-11-16 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for flecainide and Ventricular Fibrillation
| Article | Year |
|---|---|
Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Ajmaline; Brugada Syndrome; Cardiopul | 2018 |
Efficacy of quinidine in high-risk patients with Brugada syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cohort Studies; | 2004 |
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; | 1990 |
Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
Topics: Algorithms; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topi | 1990 |
The treatment of ventricular rhythm disturbances.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premat | 1986 |
2 trials available for flecainide and Ventricular Fibrillation
| Article | Year |
|---|---|
Association between ease of suppression of ventricular arrhythmia and survival.
Topics: Aged; Cross-Over Studies; Encainide; Flecainide; Follow-Up Studies; Humans; Middle Aged; Moricizine; | 1995 |
Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Bundle-Branch Block; Disopyramide; Electrocardiography; Flecain | 2000 |
70 other studies available for flecainide and Ventricular Fibrillation
| Article | Year |
|---|---|
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long | 2022 |
Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Electrocardiogra | 2021 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
Shock-resistant ventricular fibrillation.
Topics: Anti-Arrhythmia Agents; Electric Countershock; Female; Flecainide; Humans; Treatment Failure; Ventri | 2014 |
Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Electrophysiologic Techniques, | 2016 |
Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Catheter Ablation; Death, Sudden | 2015 |
Effect of flecainide on suppression of ventricular fibrillation in a patient with early repolarization syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Male; Ventric | 2016 |
Reply to the Editor- Effect of Flecainide on Suppression of Ventricular Fibrillation in a Patient With Early Repolarization Syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Ventricular F | 2016 |
To the Editor-Flecainide and ventricular fibrillation in patients with early repolarization syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Humans; Ventricular F | 2016 |
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.
Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Biomarkers; Brugada Syndrome; Electrocardiography; Female; | 2010 |
Atypical ST segment elevation and ventricular fibrillation without structural heart disease: a new electrocardiographic presentation of a channelopathy?
Topics: Anti-Arrhythmia Agents; Brugada Syndrome; Channelopathies; Death, Sudden, Cardiac; Defibrillators, I | 2010 |
Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Evalu | 2010 |
Na+ channel distribution and electrophysiological heterogeneities in guinea pig ventricular wall.
Topics: Action Potentials; Animals; Electrocardiography; Flecainide; Guinea Pigs; Heart Conduction System; M | 2011 |
Effects of ventricular pacing protocol on electrical restitution assessments in guinea-pig heart.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Flecainide; Guinea Pigs; Heart Ventricles; I | 2012 |
[Normal conventional electrocardiogram with negative pharmacological stress test does not rule out Brugada syndrome].
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardiography; Exe | 2003 |
Flecainide test in Brugada syndrome: a reproducible but risky tool.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi | 2003 |
Flecainide induced ventricular fibrillation in a neonate.
Topics: Anti-Arrhythmia Agents; Fatal Outcome; Flecainide; Humans; Infant, Newborn; Tachycardia, Supraventri | 2003 |
Refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation by flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Cats; Electrocardiography; Entropy; Flecainide; Fourier Analysis; H | 2003 |
[Can myocardial Na+ channel gene mutation be a prognostic factor for sudden death in asymptomatic Brugada syndrome?].
Topics: Death, Sudden, Cardiac; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Mutation; NAV1.5 | 2004 |
Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Defibrillators, Implantable; Electric Stimulatio | 2005 |
[Study of flecainide in the treatment of ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; | 1983 |
Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Dogs; Electric Stimulation; Female; F | 1983 |
Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Clinical Protocols; Combined Modality Therapy; Defibrillators, Implan | 1995 |
Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
Topics: Animals; Autonomic Nervous System; Cardiac Complexes, Premature; Cats; Electrocardiography; Flecaini | 1994 |
Antifibrillatory effects of class III antiarrhythmic drugs: comparative study with flecainide.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Dogs; Electric Stimulati | 1993 |
Prolongation of intraventricular conduction time associated with fatal [correction of fetal] impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Defibrillators, Implantable; Disopyramide; Do | 1995 |
Changes in canine ventricular fibrillation threshold induced by verapamil, flecainide and bretylium.
Topics: Animals; Bretylium Compounds; Cardiac Pacing, Artificial; Dogs; Electrocardiography; Flecainide; Ven | 1993 |
Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Benzamides; Disease Models, Animal; Flecainid | 1995 |
Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Electric Countershock; Encainide; | 1996 |
Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Diltiazem; Dogs; Electrocardi | 1996 |
Effects of blockade of fast and slow inward current channels on ventricular fibrillation in the pig heart.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disopyramide; Electrocardiography; Flecai | 1996 |
Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Vessels; Disopyramide; Electric Stimulatio | 1997 |
Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Disopyramide; Dogs; Electric Conducti | 1997 |
Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dilatation, Pathologic; Electrocardiography; Fle | 1998 |
Effects of lidocaine and mexiletine on defibrillation energy requirements in animals treated with flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Dogs; Electric Countershock; Flecainide; Lidocaine; Mexiletine; Ven | 1998 |
ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Electroc | 1998 |
Intracoronary flecainide induces ST alternans and reentrant arrhythmia on intact canine heart: A role of 4-aminopyridine-sensitive current.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disopyrami | 1999 |
A case of vasospastic angina presenting Brugada-type ECG abnormalities.
Topics: Acetylcholine; Aged; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular Agents; Chest | 1999 |
Relation between activation sequence fluctuation and arrhythmogenicity in sodium-channel blockades.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Flecainide; Heart; Sodium Channel Block | 1999 |
Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Flecainide; Myocardial | 2000 |
Alteration of ventricular fibrillation by flecainide, verapamil, and sotalol: an experimental study.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrophysiology; Flecainide; Heart Co | 2000 |
Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome.
Topics: Adrenergic beta-Agonists; Adult; Ajmaline; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Paci | 2000 |
Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electr | 2000 |
Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome.
Topics: Adult; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Quinidine; Syndrome; Treatment Ou | 2001 |
Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Electrocardiography; Fl | 2002 |
Amiodarone used in successful resuscitation after near-fatal flecainide overdose.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Drug Overdose; Female; Flecainide | 2002 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
Role of asynchronous activation of the ventricular fibres by an ectopic pacemaker in the accidents, especially fibrillation, caused by Ic antiarrhythmic drugs.
Topics: Animals; Anti-Arrhythmia Agents; Female; Flecainide; Heart Conduction System; Male; Myocardial Ische | 1992 |
Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Coronary Disease; Electric Stimulation; Electrocardiography, Ambulatory; Exercise Test; Female | 1990 |
Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias.
Topics: Aged; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Exercise Test; Fem | 1990 |
[Successful multiple resuscitation in flecainide poisoning].
Topics: Adult; Electric Countershock; Electrocardiography; Female; Flecainide; Follow-Up Studies; Heart Arre | 1992 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Flecainide; Heart Conduction System; In V | 1991 |
Class Ic antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Disease; Coronary Vesse | 1991 |
Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysi | 1990 |
[Ventricular fibrillation in a patient with ventricular dysplasia and mitral valve prolapse].
Topics: Adult; Electric Countershock; Electrocardiography; Flecainide; Heart Ventricles; Humans; Male; Mitra | 1990 |
Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs.
Topics: Animals; Dose-Response Relationship, Drug; Electric Countershock; Electrophysiology; Flecainide; Swi | 1988 |
Effects of flecainide on occlusion and reperfusion arrhythmias in dogs.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Electrocardiography; Flecainide; Heart Rate; Myocar | 1989 |
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Electrocardiography; Exercise Test; | 1989 |
Effects of flecainide on defibrillation thresholds in the anesthetized dog.
Topics: Animals; Cardiac Pacing, Artificial; Dogs; Electric Countershock; Electrocardiography; Female; Fleca | 1989 |
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].
Topics: Electrocardiography; Female; Flecainide; Heart Valve Prosthesis; Humans; Magnesium; Middle Aged; Mit | 1989 |
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death.
Topics: Animals; Death, Sudden; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electric Stimula | 1987 |
Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect.
Topics: Adult; Aged; Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Male; Middle Aged; P | 1987 |
Flecainide--an intravenous infusion regimen.
Topics: Aged; Female; Flecainide; Humans; Infusions, Intravenous; Male; Middle Aged; Tachycardia; Ventricula | 1987 |
A paradoxical response to arrhythmia therapy.
Topics: Electrocardiography; Flecainide; Heart Ventricles; Humans; Male; Middle Aged; Tachycardia; Ventricul | 1987 |
Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction.
Topics: Animals; Blood Pressure; Dogs; Electric Stimulation; Female; Flecainide; Heart Rate; Male; Myocardia | 1987 |
Flecainide acetate in dogs with ischemic tachyarrhythmia. An electrophysiologic study.
Topics: Animals; Dogs; Flecainide; Heart Conduction System; Myocardial Infarction; Tachycardia; Ventricular | 1988 |
Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Mi | 1986 |
Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers.
Topics: Animals; Anti-Arrhythmia Agents; Chloroform; Dogs; Female; Flecainide; Magnetic Resonance Spectrosco | 1986 |
Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; | 1985 |